ALK2/RIPK2 dual selective inhibitor (Tufts medical university/University of Houston)

N/A

Report date: 2025/03/18 18:08:02
NME

Base Information

Drug NameALK2/RIPK2 dual selective inhibitor (Tufts medical university/University of Houston)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionActivin receptor type-1 inhibitorsSerine/threonine-protein kinase RIPK2 inhibitors
TargetsSerine/threonine-protein kinase RIPK2Activin receptor type-1
Therapy Area/IndicationsInflammationMultiple SclerosisEnterocolitis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTufts University
China Registration ClassN/A

Develop Information

Active CompaniesTufts UniversityUniversity Of Houston
Inactive CompaniesN/A
Active IndicationsInflammationMultiple SclerosisEnterocolitis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A